Hata, Reo
Yamashita, Yugo
Morimoto, Takeshi
Kadota, Kazushige
Amano, Hidewo
Murai, Ryosuke
Osakada, Kohei
Sano, Arata
Takase, Toru
Hiramori, Seiichi
Kim, Kitae
Oi, Maki
Akao, Masaharu
Doi, Kosuke
Kobayashi, Yohei
Toyofuku, Mamoru
Izumi, Toshiaki
Tada, Tomohisa
Chen, Po-Min
Murata, Koichiro
Tsuyuki, Yoshiaki
Saga, Syunsuke
Nishimoto, Yuji
Sasa, Tomoki
Sakamoto, Jiro
Kinoshita, Minako
Togi, Kiyonori
Mabuchi, Hiroshi
Takabayashi, Kensuke
Tsujisaka, Yuta
Seko, Yuta
Matsushita, Kazuki
Yoneda, Fumiya
Kato, Takao
Ono, Koh
Kimura, Takeshi
,
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
Article History
Accepted: 31 August 2021
First Online: 15 September 2021
Declarations
:
: Dr. Yamashita received lecture fees from Daiichi-Sankyo, Pfizer, Bristol-Myers Squibb, and Bayer Healthcare. Dr. Morimoto received lecture fees from Mitsubishi Tanabe Pharma and Pfizer Japan and consultant fees from Asahi Kasei, Bristol-Myers Squibb, and Boston Scientific. Dr. Akao received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare and Daiichi-Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Kyoto University Hospital Ethics Committee approved this study (the approval number R0493).
: Not applicable.
: Not applicable.